menu
    • menu
    [{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK|DYRK||Wnt signaling pathway (Wnt pathway)","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase II","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"||CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Asociaci\u00f3n Europea y Latinoamericana SELNET para la Investigaci\u00f3n en Sarcomas","sponsor":"Biosplice","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK|DYRK","graph1":"Oncology","graph2":"Phase II","graph3":"Asociaci\u00f3n Europea y Latinoamericana SELNET para la Investigaci\u00f3n en Sarcomas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asociaci\u00f3n Europea y Latinoamericana SELNET para la Investigaci\u00f3n en Sarcomas \/ Biosplice","highestDevelopmentStatusID":"8","companyTruncated":"Asociaci\u00f3n Europea y Latinoamericana SELNET para la Investigaci\u00f3n en Sarcomas \/ Biosplice"}]

    Find Clinical Drug Pipeline Developments & Deals for Cirtuvivint

    Menu

    Cirtuvivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

                            Country arrow
                            PackExpo
                            Not Confirmed

                            Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

                            Country arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Biosplice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

                            Details : Cirtuvivint is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2025

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Biosplice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosplice Doses First Patient in Phase 2 Cirtuvivint Trial for Soft-Tissue Cancer

                            Details : SM08502 (cirtuvivint) is a small molecule inhibitor of CLK and DYRK kinases, being investigated for the treatement of advanced soft-tissue sarcomas.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2025

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biosplice Begins AML and MDS Trials Sponsored By National Cancer Institute

                            Details : The collaboration aims for Biosplice to expand its clinical candidate, SM08502 (cirtuvivint), as a standalone treatment and combination therapy in patients with AML and MDS.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 12, 2024

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clini...

                            Details : Cirtuvivint (SM08502) is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2022

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology

                            Details : Cirtuvivint is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2021

                            Lead Product(s) : Cirtuvivint,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combi...

                            Details : SM08502 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2021

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Biosplice

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced So...

                            Details : SM08502 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 28, 2017

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth